Literature DB >> 6202830

Monoclonal antibodies to hepatitis Be antigen (HBeAg) derived from hepatitis B core antigen (HBcAg): their use in characterization and detection of HBeAg.

R B Ferns, R S Tedder.   

Abstract

A panel of mouse hybridomas secreting monoclonal antibody to serum hepatitis Be antigen (HBeAg) was produced from mice immunized with denatured hepatitis B core antigen (HBcAg). This panel could be divided broadly into two groups. Within each group, the monoclonal antibodies recognized a single antigenic site, designated either e-alpha or e-beta, and generally exhibited a high degree of cross-inhibition. In contrast, between the two groups of antibodies there was little or no cross-inhibition. The antigens of serum HBeAg and denatured HBcAg appeared to be very similar. Both behaved as molecules carrying only a single e-alpha or e-beta site, in spite of native serum HBeAg having an apparent molecular weight of 300 000. It is inferred that e-alpha and e-beta sites may be involved in the polymerization of HBeAg into HBcAg and that during this process mutual masking of antigenic sites may occur.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202830     DOI: 10.1099/0022-1317-65-5-899

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Diversity of core antigen epitopes of hepatitis B virus.

Authors:  D M Belnap; N R Watts; J F Conway; N Cheng; S J Stahl; P T Wingfield; A C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-03       Impact factor: 11.205

2.  Non-canonical binding of an antibody resembling a naïve B cell receptor immunoglobulin to hepatitis B virus capsids.

Authors:  Norman R Watts; Giovanni Cardone; Joe G Vethanayagam; Naiqian Cheng; Catharina Hultgren; Stephen J Stahl; Alasdair C Steven; Matti Sällberg; Paul T Wingfield
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

3.  The affinities of monoclonal antibodies against core antigen of hepatitis B virus.

Authors:  U Apsalons; V Bichko
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens.

Authors:  M Sällberg; K Townsend; M Chen; J O'Dea; T Banks; D J Jolly; S M Chang; W T Lee; D R Milich
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

5.  Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus.

Authors:  J Salfeld; E Pfaff; M Noah; H Schaller
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids.

Authors:  A Gallina; F Bonelli; L Zentilin; G Rindi; M Muttini; G Milanesi
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

7.  Chimeric rabbit/human Fab antibodies against the hepatitis Be-antigen and their potential applications in assays, characterization, and therapy.

Authors:  Xiaolei Zhuang; Norman R Watts; Ira W Palmer; Joshua D Kaufman; Altaira D Dearborn; Joni L Trenbeath; Elif Eren; Alasdair C Steven; Christoph Rader; Paul T Wingfield
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

8.  IgG subclasses in circulating immune complexes with hepatitis B e antigen in chronic hepatitis B.

Authors:  M Sällberg; H Norder; G Lindh; L O Magnius
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

9.  Immunohistological study of intrahepatic expression of hepatitis B core and E antigens in chronic type B hepatitis.

Authors:  C M Chu; Y F Liaw
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

10.  Relevance of cysteine residues for biosynthesis and antigenicity of human hepatitis B virus e protein.

Authors:  G Wasenauer; J Köck; H J Schlicht
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.